These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18060334)

  • 41. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
    Kaya A; Aydin N; Topsever P; Filiz M; Oztürk A; Dağar A; Kilinç E; Ekmekcioglu C
    Biomed Pharmacother; 2004 Dec; 58(10):582-7. PubMed ID: 15589067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacotherapy to reduce visceral fat.
    Blackburn GL; Waltman BA
    Clin Cornerstone; 2005; 7(2-3):52-60. PubMed ID: 16473261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological treatment of obesity.
    Mancini MC; Halpern A
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacotherapy for obesity.
    Halford JC
    Appetite; 2006 Jan; 46(1):6-10. PubMed ID: 16229924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [What effect does losing weight have on hypertension?].
    Engeli S
    MMW Fortschr Med; 2003 Jul; 145(27-28):44. PubMed ID: 14587188
    [No Abstract]   [Full Text] [Related]  

  • 47. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
    Chaput JP; St-Pierre S; Tremblay A
    Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacologic treatment of obesity.
    Sidhaye A; Cheskin LJ
    Adv Psychosom Med; 2006; 27():42-52. PubMed ID: 16418541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pharmacotherapy of obesity].
    Tripp B; Ludvik B
    Wien Med Wochenschr; 2004 Jul; 154(13-14):320-8. PubMed ID: 15368953
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rimonabant, obesity and diabetes.
    Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
    Viner RM; Hsia Y; Tomsic T; Wong IC
    Obes Rev; 2010 Aug; 11(8):593-602. PubMed ID: 19922432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral administration of the antiobesity drugs, sibutramine and rimonabant, increases acetylcholine efflux selectively in the medial prefrontal cortex of the rat.
    Davis RJ; Nomikos GG
    Mol Psychiatry; 2008 Mar; 13(3):240-1. PubMed ID: 18285757
    [No Abstract]   [Full Text] [Related]  

  • 56. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.
    Coutinho W
    Arq Bras Endocrinol Metabol; 2009 Mar; 53(2):262-70. PubMed ID: 19466219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
    Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U
    Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacologic treatment for obesity. Options for today...and tomorrow.
    Lundquist LM; Sirimaturos M; Cannon E
    Adv Nurse Pract; 2006 Aug; 14(8):31-5, 64. PubMed ID: 16972485
    [No Abstract]   [Full Text] [Related]  

  • 59. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.
    Neovius M; Narbro K
    Int J Obes (Lond); 2008 Dec; 32(12):1752-63. PubMed ID: 18982009
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Weight loss via drug therapy].
    Wirth A
    Internist (Berl); 2003 Mar; 44(3):359-62, 363-6. PubMed ID: 12731423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.